icosapent ethyl
Brand: Vascepa
Prototype Drug
Drug Class: omega-3 fatty acid cardiovascular agent
Drug Family: antilipemic
Subclass: purified EPA ethyl ester
Organ Systems: cardiovascular
Mechanism of Action
Purified eicosapentaenoic acid (EPA) ethyl ester that reduces hepatic VLDL-triglyceride synthesis and secretion, enhances triglyceride clearance, and exerts anti-inflammatory and anti-atherosclerotic effects independent of triglyceride lowering — mechanisms underlying the cardiovascular mortality benefit observed in REDUCE-IT.
hepatic triglyceride synthesisVLDL productionplatelet aggregation (partial inhibition)
Indications
- severe hypertriglyceridemia (500 mg/dL or greater)
- cardiovascular risk reduction in patients with elevated triglycerides on maximally tolerated statin therapy with established CVD or diabetes plus 2 or more CVD risk factors
Contraindications
- known hypersensitivity to icosapent ethyl or omega-3 fatty acids
- fish or shellfish allergy
Adverse Effects
Common
- musculoskeletal pain
- peripheral edema
- atrial fibrillation
- arthralgia
- oropharyngeal pain
Serious
- atrial fibrillation and flutter (increased risk)
- serious bleeding (especially with anticoagulants)
Pharmacokinetics (ADME)
| Absorption | oral capsules; absorption enhanced with food (high-fat meal); de-esterified to EPA after absorption |
| Distribution | incorporated into phospholipid membranes and plasma lipoproteins; Vd extensive |
| Metabolism | de-esterification to EPA, then beta-oxidation and omega-oxidation; not CYP450 substrate |
| Excretion | primarily via metabolism; minimal renal excretion of intact drug |
| Half-life | approximately 89 hours at steady-state |
| Onset | triglyceride reduction within weeks; CV benefit over years |
| Peak | 5 hours |
| Duration | steady-state achieved in approximately 2 weeks |
| Protein Binding | >99% (EPA) |
| Vd | extensive (membrane-incorporated) |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| anticoagulants (warfarin, direct oral anticoagulants) | additive antiplatelet/anticoagulant effects increase bleeding risk | moderate |
| antiplatelet agents (aspirin, clopidogrel) | additive platelet inhibition may increase bleeding | moderate |
Nursing Considerations
- Administer capsules with food (preferably a high-fat meal) to enhance absorption; capsules must be swallowed whole and not crushed or chewed.
- Monitor for atrial fibrillation or flutter, particularly in patients with existing AF risk; instruct patients to report palpitations, shortness of breath, or irregular heartbeat.
- Assess bleeding risk in patients on anticoagulants or antiplatelet agents; monitor for unusual bruising or bleeding.
- Counsel patients with fish or shellfish allergy about potential hypersensitivity; screen for allergy history before initiating therapy.
Clinical Pearls
- The REDUCE-IT trial demonstrated a 25% relative risk reduction in major adverse cardiovascular events with icosapent ethyl 4 g/day added to statins — a landmark finding that changed guidelines for triglyceride-lowering therapy.
- Unlike mixed omega-3 preparations (fish oil with EPA+DHA), icosapent ethyl contains purified EPA only; DHA may raise LDL-C, and the cardiovascular benefit appears EPA-specific in current evidence.
Safety Profile
Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Guideline Update pending
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.